Results 81 to 90 of about 5,445 (182)

Effects of tolvaptan on renal function in chronic kidney disease patients with volume overload

, 2018
Shunji Suzuki,1,2 Norio Hanafusa,3 Kenji Kubota,1 Ken Tsuchiya,3 Kosaku Nitta2 1Department of Nephrology, Kawaguchi Saiseikai Hospital, Kawaguchi, Japan; 2Department of Medicine, Kidney Center, Tokyo Women’s Medical University, Tokyo, Japan ...
Tsuchiya K, Kubota K, Suzuki S, Nitta K, Hanafusa N   +4 more
core  

Effects and safety of oral tolvaptan in patients with congestive heart failure: A systematic review and network meta-analysis.

PLoS ONE, 2017
AimsSeveral studies reported treatment benefits of tolvaptan in patients with congestive heart failure (CHF). However, the optimal dosage remains unclear.
Mei-Yi Wu, Tzu-Ting Chen, Ying-Chun Chen, Der-Cherng Tarng, Yun-Chun Wu, Hsien-Ho Lin, Yu-Kang Tu   +6 more
doaj   +1 more source

Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial [Corrigendum]

, 2018
Muto S, Okada T, Yasuda M, et al. Drug Healthc Patient Saf. 2017;9:93–104.On page 97, ‘Discussion’ section, lines 10–13, left column, the sentence: ‘Similarly, placebo patients who crossed over onto active treatment ...
Nakajima K, Yasuda M, Horie S, Muto S, Tsubouchi H, Okada T   +5 more
core  

SHORT COMMUNICATION Hepatocellular Disposition and Transporter Interactions with Tolvaptan and Metabolites in Sandwich-Cultured Human Hepatocytes Running Title: Tolvaptan Disposition and DDIs in SCHH

, 2020
: Tolvaptan is a selective V 2 -receptor antagonist primarily metabolized by CYP3A. The present study investigated the hepatocellular disposition of tolvaptan and the generated tolvaptan metabolites, DM-4103 and DM-4107, as well as the potential for drug-
K L R, J R S, ( Y L
core  

Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial

, 2017
Satoru Muto,1 Tadashi Okada,2 Moriyoshi Yasuda,3 Hidetsugu Tsubouchi,4 Koji Nakajima,4 Shigeo Horie1,5 1Department of Advanced Informatics for Genetic Disease, Juntendo University Graduate School of Medicine, Tokyo, 2Department of Clinical Development ...
Nakajima K, Yasuda M, Horie S, Muto S, Tsubouchi H, Okada T   +5 more
core  

Comparison of the change in annual growth rate of total kidney volume between the tolvaptan group and the non-tolvaptan group.

, 2022
The median difference in the annual change in TKV was not statistically different between the tolvaptan group (0.2 (range -30.3, 22.5)) and the non-tolvaptan group (2.0 (-15.6, 16.6)) (p = 0.39, Wilcoxon rank sum test).
Akinari Sekine (4357189), Eiko Hasegawa (848440), Naoki Sawa (848442), Hiroki Mizuno (560647), Tatsuya Suwabe (848436), Masayuki Yamanouchi (848441), Junichi Hoshino (848432), Daisuke Ikuma (12102061), Yoshifumi Ubara (848444)   +8 more
core   +1 more source

The long-term effect of tolvaptan treatment on kidney function and volume in patients with ADPKD. [PDF]

Nephrol Dial Transplant
BACKGROUND AND HYPOTHESIS: The only therapy to ameliorate disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD) is tolvaptan, a vasopressin V2 receptor antagonist.
Geertsema P, Bais T, Kuiken V, Knol MGE, Casteleijn NF, Vart P, Meijer E, Gansevoort RT.   +7 more
europepmc   +2 more sources

Formulation Approaches for Improving the Dissolution Behavior and Bioavailability of Tolvaptan Using SMEDDS

, 2022
Tolvaptan, a selective vasopressin receptor antagonist, is a Class IV agent of Biopharmaceutical Classification System (BCS). To improve bioavailability after oral administration, the new tolvaptan-loaded self-microemulsifying drug delivery system ...
Gye-Won Lee, Jong-Hwa Lee
core   +1 more source

Short term efficacy and safety of low dose tolvaptan in patients with acute decompensated heart failure with hyponatremia: a prospective observational pilot study from a single center in South India

Heart Views, 2014
Background: In acute decompensated heart failure (ADHF), diuretic use, the mainstay therapy for congestion, is associated with electrolyte abnormalities and worsening renal function. Vasopressin mediates fluid retention in heart failure.
Soumya Patra, Basant Kumar, Kaushal K Harlalka, Apoorva Jain, H M Bhanuprakash, K S Sadananda, Harsha Basappa, K Santhosh, K S Rajith, K S Bharathi, C N Manjunath   +10 more
doaj   +1 more source

Tolvaptan in Autosomal Dominant Polycystic Kidney Disease

, 2011
Summary Background and objectives: Autosomal dominant polycystic kidney disease (ADPKD), a frequent cause of end-stage renal disease, has no cure. V2-specific vasopressin receptor antagonists delay disease progression in animal models.
Vicente E. Torres, Grantham, Jared J., Eiji Higashihara, Torres, Vicente E., Chapman, Arlene B., Krasa, Holly B., Kikuo Nutahara, Higashihara, Eiji, Horie, Shigeo, Bae, Kyongtae, Kyongtae Bae, Jared J. Grantham, Watnick, Terry J., Arlene B. Chapman, Terry J. Watnick, Nutahara, Kikuo, Ouyang, John, Shigeo Horie, John Ouyang, Holly B. Krasa, Czerwiec, Frank S., Frank S. Czerwiec   +21 more
core   +1 more source